Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — JMP Securities Life Sciences Conference 2022
26 slides from Cognition Therapeutics's conference presentation, Jun 16, 2022
Slide 1: Disease-modifying medicines for degenerative disorders
Disease - modifying medicines for degenerative disorders JMP Securities Life Sciences Conference June 16, 2022
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including
Slide 3: Who We Are
3 Who We Are Targeting unmet needs in age - related degenerative disorders of the central nervous system and retina such as Alzheimer’s disease, dementia with Lewy bodies (DLB), dry age - related macular degeneration (dry AMD), and Parkinson’s disease Functionally distinct therapeutic approach focus
Slide 4: Product candidate pipeline
4 Product Candidate Target Indication Preclinical Phase 1 Phase 2 Phase 3 Funding CT1812 SEQUEL Mild - moderate AD $3.3M CT1812 SHINE Mild - moderate AD $30M CT1812 START Early - stage AD $81M CT1812 SHIMMER DLB $30M CT1812 Dry AMD * CT2168 Synucleinopathies † CT2074 Dry AMD Pipeline * Provided the
Slide 5: Grants Continue to Provide Funding
5 Clinical Study Total Awarded Remaining (yet to be drawn down) START (early AD) $ 81 Million $ 69 Million SHINE (mild/mod AD) $ 30 Million $ 13 Million SHIMMER (DLB) $ 29 Million $ 27 Million SEQUEL ( qEEG in AD) $ 3.3 Million $ 0.8 Million $ 144 Million $ 110 Million Approximately 50% of R&D Funde
Slide 6: Key Upcoming Milestones
6 Completing • PK • Human AME • SEQUEL Conducting • SHINE (cohort 2) • Phase 2 in DLB • Phase 2 with ACTC • Phase 2 in dry AMD * • IND - enabling studies for research compounds Key Upcoming Milestones * Subject to discussion with FDA 2021 2022 2023 Completed x SNAP x SPARC x SHINE (cohort 1) Complet
Slide 7: Review of CT1812 for the Treatment of Alzheimer's Disease
Review of CT1812 for the Treatment of Alzheimer’s Disease Cognition Lead Program:
Slide 8: Alzheimer's Disease Market Overview
8 • Approx. 6.2 million individuals in United States are afflicted with Alzheimer’s disease 1 - Approximately 35 million people worldwide 2 - Prevalence expected to double by 2050 1 • Direct healthcare costs for patients with Alzheimer’s and other dementias is estimated to exceed $300 billion in the
Slide 9: CT1812: A Synaptoprotective Approach to Alzheimer's Disease
9 • CT1812 penetrates the blood - brain barrier (BBB) and binds selectively to the σ - 2 receptor • By modulating σ - 2, CT1812 displaces and prevents oligomers from binding to neurons and clears them into CSF • Prevents synaptotoxicity and facilitates restoration of neuronal function • CT1812 mimic
Slide 10: Evidence of Target Engagement: SNAP (COG0104)
10 Evidence of Target Engagement: SNAP (COG0104) First evidence of target engagement in humans, mirrors preclinical findings, corroborating our mechanism of action …and now in people with Alzheimer’s disease CT1812 oligomer receptor complex PGRMC1 σ - 2 receptor complex TMEM97 This displacement can
Slide 11: SHINE interim analysis yields promising evidence
11 • 3 - point difference (ADAS - COG) between treated and untreated patients at day 185 • Clinically meaningful magnitude of change • Trend for improved cognitive outcomes Cognitive & Biological Outcomes • Statistically significantly lower A β protein (p=0.017) in treated vs placebo patients • Addi
Slide 12: SPARC (COG0105) Results
12 1 ° Endpoint: evaluate safety and tolerability of CT1812 Results: • Safety profile consistent with prior studies • Trend towards preservation of brain volume (composite) in treated patients vs placebo • Statistically significant (p<0.05) improvement in volume in three regions (bottom right) • No
Slide 13: SEQUEL (COG0202)
13 • Principal investigator: E. Vijverberg , MD, PhD; neurologist at Vumc Alzheimer’s Center • Single - site quantitative EEG study in patients with mild - to - moderate AD • Two group cross over design • Objective: evaluate the efficacy of CT1812 in restoring synaptic function through quantitative
Slide 14: START Phase 2 study in early Alzheimer's disease
14 Phase 2 efficacy study, powered to show change in cognition: slowing or halting cognitive decline • Enrolling ~540 patients with early Alzheimer’s disease at ~35 leading academic U.S. sites • Initiation in 2H 2022 • Grant awarded in collaboration with ACTC: premier Alzheimer’s clinical trial grou
Slide 15: Pharmacodynamic Biomarkers of CT1812 Discovered in SHINE
15 Identified PD Biomarkers Associated with Alzheimer’s Pathology Normalized by CT1812 in SHINE Biomarkers normalized by CT1812 Most Highly Represented Pathways Pharmacodynamic Biomarkers of CT1812 Discovered M4 Synapse/Neuron M3 Oligo/Myelination M1 Synapse/Neuron M21 MHC Complex/Immune M42 Matriso
Slide 16: Synucleinopathies
Synucleinopathies Disorders such as DLB and Parkinson’s disease that are characterized by deposits of α - synuclein aggregates (called Lewy bodies) that disrupt key cellular processes Cognition Pipeline:
Slide 17: Synucleinopathies are 2nd only to AD in Prevalence
17 • In the U.S., approximately 13 million people have a form of dementia 1 - Dementia with Lewy bodies (DLB): 1.4 million - PD: 1 million • Direct healthcare costs: - DLB: $31.5 billion 2 - PD: $25 billion 3 Synucleinopathies are 2nd only to AD in Prevalence Parkinson's Disease DLB Alzheimer's Dise
Slide 18: Sigma-2 Modulators May be Disease Modifying in Synucleinopathies
18 σ - 2 Modulators May be Disease Modifying in Synucleinopathies Cellular evidence that σ - 2 modulators have a beneficial impact α - synuclein oligomer - induced trafficking deficits (red) are reversed by Cognition drug (black) Cognition antagonists block the binding / internalization of α - synuc
Slide 19: DLB Phase 2 SHIMMER Study
19 • Principal investigator: James E. Galvin, MD, MPH, professor of neurology and director of the Comprehensive Center for Brain Health • Phase 2 trial ongoing • U Miami and 20+ academic sites • Archived DLB R&D educational symposium available: https://ir.cogrx.com DLB Phase 2 Funded with ~$30M NIA
Slide 20: Dry Age-related Macular Degeneration
Dry Age - related Macular Degeneration Cognition Pipeline:
Slide 21: Rationale for Sigma-2 Modulators in Dry AMD
21 σ - 2 receptors • Expression: in RPE cells, retinal ganglion cells, photoreceptors in retina • Biology : Regulates autophagy, protein trafficking, lipid metabolism dysregulated in AMD • Target validation: TMEM97 knockdown is protective • Human genetics: Linked to dry AMD σ - 2 receptor modulators
Slide 22: Sigma-2 Receptor Modulators Prevent Trafficking Deficits
22 • Aβ oligomers and oxidative stress cause lysosomal deficits in capacity to traffic & degrade photoreceptor outer segments (POS) cargos in RPE cells • σ - 2 receptor modulators from 3 chemically distinct series rescued these deficits Results: σ - 2 Receptor Modulators Prevent Deficits in Traffick
Slide 23: Support for Moving Forward with CT1812 for dAMD
23 Genetic, Clinical Biomarker and Preclinical Data Support Moving Forward with CT1812 for dAMD * Subject to discussion with FDA Assessments such as: Change in GA lesion Low luminance visual acuity (LLVA) Best - corrected visual acuity (BCVA) Study Drug Administration Screening: Age: ≥ 50 Diagnosis
Slide 24: Financial Position
Financial Position Financials as of March 31, 2022 • Cash and Cash Equivalents: $52.5 million • Proceeds raised from IPO: $52.0 million • Sufficient cash runway into 2H 2023 NIA funding for CT1812 studies as of Dec 31, 2021 • Preclinical through Phase 2 studies $168.4 million • Approximate funding u
Slide 25: Thank You
Thank You James O’Brien Chief Financial Officer 203 - 536 - 1797 jobrien@cogrx.com Lisa Ricciardi President & CEO 917 - 658 - 5789 lricciardi@cogrx.com
Slide 26: Membrane Trafficking Screening Assay
26 Membrane Trafficking Screening Assay Novel phenotypic screening assay - Neurons - A β oligomer toxin - Membrane trafficking readout Novel proprietary chemical library More than 10k compounds screened Candidate identification and development 5 distinct chemical series, each with 100s of analogues
Cognition Therapeutics — JMP Securities Life Sciences Conference 2022 on 6ix